Shineway’s 2022 performance was outstanding. As its TCM formula granules business would seize more market share, Shineway will keep high growth in 2023. It's undervalued considering large cash balance
Boomeranged on Fri, 4 Aug 2023 09:49
Shineway released positive profit alert for 23H1. The peak of COVID infection in 22Q1/23Q1 increased the demand for TCM products. Although TCM formula granules business is another driver to offset the slowdown of COVID related TCM after pandemic is under control, ensuring strong overall growth in 2023, the growth in 23H2 could slowdown. So, profit-taking is a good idea when valuation isn't cheap.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.